Clinical Trial

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

Study acronym: ACROBAT
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA. Before transplant, patient and donor peripheral blood sample will be collected to identify informative marker for routine chimerism testing and baseline establishment for AlloHeme. Post-transplant blood or bone marrow samples are obtained and compared to the baseline sample profiles to calculate % chimerism of recipient cells in the blood and/or bone marrow samples. Cell selection from blood and bone marrow samples is applied to evaluate chimerism in specific cell subtypes that are relevant to AML and MDS diseases (CD3+ T lymphocytes, CD33+ Myeloid cells and CD15+ Granulocyte cell subtypes from blood and CD34+ hematopoietic stem cells from bone marrow).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-11-12; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2024-10-24
Status change: Not Yet Recruiting → Recruiting 2022-04-15
Trial Details
NCT Number NCT04635384
Lead Sponsor CareDx
Conditions Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Enrollment 307 participants
Start Date 2021-06-30
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-18